Mechelen, Belgium; 15 July 2015 - Galapagos NV (Euronext & NASDAQ: GLPG)
announced today that it has entered into a licensing agreement with the HUB
foundation for use of Organoid Technology for pre-clinical research in cystic
fibrosis (CF) and inflammatory bowel disease (IBD) ...
↧